cyclohexyl-(2-phenylquinazolin-4-yl)-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: cyclohexyl-(2-phenylquinazolin-4-yl)-amine
• 英文别名: cyclohexyl(2-phenylquinazolin-4-yl)amine；N-cyclohexyl-2-phenylquinazolin-4-amine
• 化学式: C₂₀H₂₁N₃
• 分子量: 303.407
• InChiKey: DIKXFQQKKWIAMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  cyclohexyl-(2-phenylquinazolin-4-yl)-amine 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 生成 cyclohexyl(2-phenylquinazolin-4-yl)amine hydrochloride
  参考文献：
  名称：

  Design and synthesis of 4-amino-2-phenylquinazolines as novel topoisomerase I inhibitors with molecular modeling

  摘要：

  4-Amino-2-phenylquinazolines 7 were designed as bioisosteres of 3-arylisoquinolinamines 6 that were energy minimized to provide stable conformers. Interestingly, the 2-phenyl ring of 4-amino-2-phenylquinazolines was parallel to the quinazoline ring and improved their DNA intercalation ability in the DNA-topo I complex. Among the synthesized 4-amino group-substituted analogs, 4-cyclohexylamino-2-phenylquinazoline 7h exhibited potent topo I inhibitory activity and strong cytotoxicity. Interestingly, consistency was observed between the cytotoxicities and topo I activities in these quinazoline analogs, suggesting that the target of 4-amino-2-phenylquinazolines is limited to topo I. Molecular docking studies were performed with the Surflex-Dock program to afford the ideal interaction mode of the compound into the binding site of the DNA-topo I complex in order to clarify the topo I activity of 7h. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.05.012
• 作为产物：
  描述：

  2-溴苯胺 在 potassium acetate 、 palladium diacetate 、 sodium hydride 、 2-(二环己基膦基)联苯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 cyclohexyl-(2-phenylquinazolin-4-yl)-amine
  参考文献：
  名称：

  钯催化的N-（2-溴代芳基）am的分子内亚胺化反应合成4-氨基喹唑啉

  摘要：

  与广泛使用羰基化Pd催化的交叉偶联反应相比，涉及异氰酸酯插入的类似反应几乎处于空白。我们研究了N-（2-溴芳基）am的分子内酰亚胺化交叉偶联，从而导致了4-氨基喹唑啉。在对钯源和负载，配体，碱，温度和溶剂的反应进行了全面优化之后，准备了一个小的4-氨基喹唑啉文库来确定该方法的范围。idine和异氰酸酯上可以容忍各种取代基，从而有效地获得了广泛的具有广泛药学意义的各种取代的4-氨基喹唑啉。

  DOI：

  10.1002/chem.201102468

文献信息

• QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY
  申请人：Lee Nam Kyu

  公开号：US20080207614A1

  公开（公告）日：2008-08-28

  The present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and body weight, and a medicine for treatment and/or prevention of diabetes and/or obesity, which comprises the compound as an active ingredient.

  本发明涉及一种新型喹唑啉衍生物，能够有效降低血糖水平和体重，以及一种用于治疗和/或预防糖尿病和/或肥胖的药物，其中该化合物作为活性成分。
• 糖尿及び肥満治療予防に有効なキナゾリン誘導体
  申请人：エスケー ケミカルズ カンパニー リミテッド

  公开号：JP2008526734A

  公开（公告）日：2008-07-24

  本発明は血糖降下、体重減少を現わす新規のキナゾリン誘導体と、この化合物を有効成分として含む糖尿及び肥満治療予防剤に関する。【選択図】図１

  本发明涉及一种新型喹唑啉衍生物，该衍生物具有降血糖和减轻体重的作用，还涉及一种含有该化合物作为活性成分的糖尿病和肥胖症治疗和预防剂。[选图] 图 1.
• Synthesis and SAR study of acridine, 2-methylquinoline and 2-phenylquinazoline analogues as anti-prion agents
  作者：H. Cope、R. Mutter、W. Heal、C. Pascoe、P. Brown、S. Pratt、B. Chen

  DOI：10.1016/j.ejmech.2006.05.002

  日期：2006.10

  Transmissible spongiform encephalopathies (TSEs) are thought to arise from aggregation of a protease resistant protein denoted PrPSc, which is a misfolded isoform of the normal cellular prion protein PrPC. Using virtual high-throughput screening we have selected structures analogous to acridine, 2-methyquinoline and 2-phenylquinazoline as potential therapeutic candidates for the treatment of TSEs. From the synthesis and screening of constructed libraries we have shown that an electron-rich aromatic ring attached through an amine linker to the position para to the ring nitrogen is beneficial to both binding to PrPC and the suppression of PrPSc accumulation for acridine and 2-methylquinoline analogues. 2-Phenylquinazoline analogues appear to utilise a different mode of action by binding at a different location and/or pose. We report IC(50)s in the nanomolar range. (c) 2006 Elsevier Masson SAS. All rights reserved.
• Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
  作者：Sung J. Lee、Yoshitaka Konishi、Dingwei T. Yu、Tamara A. Miskowski、Christopher M. Riviello、Orest T. Macina、Manton R. Frierson、Kigen Kondo、Masafumi Sugitani

  DOI：10.1021/jm00018a014

  日期：1995.9

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.
• US7763627B2
  申请人：——

  公开号：US7763627B2

  公开（公告）日：2010-07-27